Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Conditions: Nonsmall Cell Lung Cancer; Performance Status Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Nab paclitaxel; Other: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13); Other: QLQ-C30 Global Health/Quality of Life Questionnaire; Other: COPD Assessment Test and modified Medical Research Coun cil Dyspnea Patient Reported Outcomes; Drug: Pemetrexed Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chronic Obstructive Pulmonary | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study